Neuronetics Inc. has announced its participation in the 2025 Clinical TMS Society Annual Meeting, where it will present significant clinical data. The company will showcase two poster presentations on June 13th, 2025. Dr. Eleanor Cole will present an analysis on the effectiveness of Transcranial Magnetic Stimulation $(TMS.AU)$ in elderly adults with Major Depressive Disorder, marking the largest study of its kind to date. Additionally, Cory Anderson will present a retrospective analysis comparing the efficacy of TMS therapy using NeuroStar and Brainsway devices, based on data from 200 Greenbrook centers. These presentations underscore Neuronetics' commitment to clinical innovation and its ongoing efforts to optimize TMS therapy. Results from these studies will be presented at the meeting, providing new insights into TMS treatment for depression.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.